Clinical trial
Glucose Optimisation With Angiotensin II Antagonist Losartan (GOAAL)
NCT00237588 · Ullevaal University Hospital, Other · Completed
Key facts
| NCT number | NCT00237588 |
|---|---|
| Title | Glucose Optimisation With Angiotensin II Antagonist Losartan (GOAAL) |
| Official title | Glucose Optimisation With Angiotensin II Antagonist Losartan in Patients With Hypertension and Other Risk Factors for Metabolic Syndrome (GOAAL) |
| Lead sponsor | Ullevaal University Hospital, Other |
| Collaborators | Merck Sharp & Dohme LLC Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | Amlodipine 10 mg or Losartan 100 mg + Amlodipine 5 mg |
| Enrollment | 25 |
| Start date | Dec 1, 2004 |
| Completion | Jul 1, 2005 |
| First posted | Oct 12, 2005 |
| Last update posted | Jul 6, 2011 |
| Countries | Norway |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: